Added to YB: 2026-09-10
Pitch date: 2026-09-08
RARE [neutral]
Ultragenyx Pharmaceutical Inc.
-3.11%
current return
Author Info
Kelin Research shares independent research on listed life sciences companies. I work from primary sources, clinical data and back-of-the-envelope valuation to answer three questions: what does the science say, what is the market pricing in, and what would prove or kill the thesis? Sign up for the newsletter.
Company Info
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific.
Market Cap
$1.5B
Pitch Price
$14.77
Price Target
24.00 (+61%)
Dividend
N/A
EV/EBITDA
-4.90
P/E
-2.63
EV/Sales
3.18
Sector
Biotechnology
Category
special_situation
A ‘RARE’ Opportunity To Dirk Ultragenyx? -40% on Tuesday.
RARE (needs more research): Ultragenyx is not compelling enough to hold through UX111’s September 19 PDUFA; any position would be very small, limited to the pre-decision run-up and exited before the binary. The $24 year-end 2027 target implies 57% upside versus 15% downside to $13, but requires cost reductions, planned financing and continued product growth, while management drag, weak operating leverage, dilution and launch or approval setbacks remain concerns.
Read full article (4 min)